Previous Close | 5.89 |
Open | 5.98 |
Bid | 5.34 x 800 |
Ask | 6.37 x 800 |
Day's Range | 5.73 - 6.15 |
52 Week Range | 5.30 - 19.75 |
Volume | |
Avg. Volume | 1,149,762 |
Market Cap | 772.197M |
Beta (5Y Monthly) | 1.59 |
PE Ratio (TTM) | 9.31 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for ORGO
CANTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2022. First Quarter 2022 Financial Results Summary: Net revenue of $98.1 million for the first quarter of 2022, a decrease of 4% (an increase of
CANTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointments of Michele Korfin and Gilberto Quintero, Ph.D. to the Company’s Board of Directors, effective May 3, 2022. Ms. Korfin and Dr. Quintero will serve as independent directors of the Compa
CANTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis, a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that the latest advanced wound care research on its PuraPly® AM, Affinity®, Apligraf®, NuShield®, Novachor™ and Organogenesis Physician Solutions product lines will be showcased at the 2022 Symposium on Advanced Wound Care (SAW